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In the past several decades, marine organisms have generously gifted to the pharmaceutical industries numerous naturally bioactive
compounds with antiviral, antibacterial, antimalarial, anti-inﬂammatory, antioxidant, and anticancer potentials. But till date only
few anticancer drugs (cytarabine, vidarabine) have been commercially developed from marine compounds while several others are
currently in diﬀerent clinical trials. Majority of these compounds were tested in the tumor xenograft models, however, lack of anti-
cancer potential data in the chemical- and/or oncogene-induced pre-initiation animal carcinogenesis models might have cost some
of the marine anticancer compounds an early exit from the clinical trials. This review critically discusses importance of preclinical
evaluation, failure of human clinical trials with certain potential anticancer agents, the screening tests used, and choice of biomarkers.
INTRODUCTION
Marine organisms provided numerous novel com-
pounds with sensational multiple pharmacological prop-
erties [1, 2, 3, 4, 5, 6, 7]. During the past 20 years, thou-
sands of novel compounds and their metabolites with di-
verse biological activities ranging from antiviral to anti-
cancer have been isolated from various marine sources
[3, 4, 5, 6]. The marine pharmacy currently holds more
than 35000 marine-derived biological samples, with ap-
proximately 150 compounds to be cytotoxic against the
tumor cells [3]. Recent reviews further suggest that ap-
proximately 35 compounds have a known mechanism(s)
of action for their antitumor eﬀect while 124 marine
compounds yet to be studied for their detailed mecha-
nism of antitumor activity [2, 4, 7]. Out of 35 antitu-
mor compounds, at least a dozen of them are currently
in various phases of human clinical trials for treatment of
diﬀerent cancers [4]. Some of the prominent anticancer
compounds in clinical trials include ecteinascidin (Yon-
delis), bryostatin-1, squalamine, aplidin, dolastatin-10,
ILX651, and KRN7000 (α-galactosylceramide) (Table 1)
[4].
PRECLINICAL EVALUATIONS AND CLINICAL TRIALS
Most of the compounds were tested in vitro by high-
throughput cost-eﬀective screening assays using exclu-
sively cancer cell lines derived from human and rodent
sources [2, 7]. Based on the in vitro antitumor activity,
several of these compounds were tested for their ther-
apeutic eﬃcacy in the tumor xenograft models in ani-
mals. However, toxicity studies in animal models are lim-
ited to only few anticancer compounds (Table 1)[ 8, 9,
10, 11, 12, 13, 14, 15, 16, 17]. Review of the published
literature on the genotoxicity and anticancer potentials
of these compounds in vivo revealed that very few com-
pounds have gone through the preclinical evaluations in
the chemical- or oncogene-induced pre-initiation animal
carcinogenesis models [4, 8, 18]. Interestingly, cytarabine
(Cytostar-U), isolated from the Caribbean sponge (Cryp-
totheca crypta) and currently being used in routine treat-
ment of patients with leukemia and lymphoma [8], seems
to be one of the very few marine anticancer drugs studied
in long-term pre-initation cancer model in F344 rats for
its anticancer eﬃcacy [19]. It showed anticancer poten-
tial by inhibiting the promoting eﬀect of mitomycin C in
N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced
bladder carcinogenesis. Recent studies further showed
that another marine compound, KRN7000, was found to
be eﬀective against methylcholanthrene (MC)-induced ﬁ-
brosarcomas, mammary carcinomas in Her-2/neu trans-
genicmice,andspontaneoussarcomasinp53-/- mice[20],
however, it was ineﬀective against BBN-induced bladder
carcinogenesis in F344 rats [21]. These results indicate
that marine anticancer compounds should be screened in
diﬀerent pre-initiation animal cancer models against sev-
eral target sites to ensure the optimum eﬃcacy prior to
the human clinical trials.
Despite the facts, there were several marine com-
pounds with anticancer potential observed in the in vitro
tests and tumor xenograft models entered into the human
clinical trials without being thoroughly investigated in the
preclinical animal models for their anticancer potentials
using diverse biological endpoint biomarkers [22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32]. Ultimately, some of them
were prematurely withdrawn from the clinical trials due
to life-threatening toxic side eﬀects in the patients.94 Jamal M. Arif et al 2004:2 (2004)
Table 1. Antitumor marine natural compounds in clinical trials with preclinical toxicity evaluation in animals.
Compound Phase of clinical trails Animal model Toxicities
Bryostatin-1 II Mice
In mice, toxicities include lethargy, unsteadiness,
haematuria, and myelosuppression [8].
Dolastatin-10 II
Mice, rats,
Maximum tolerated doses of 1350µg/m2 (mice),
dogs 450µg/m2 (rats), and ∼ 400µg/m2 (dogs); Myelotoxicity
was the most severe dose-limiting eﬀect [9].
LU103793a II N/A
Toxic eﬀects in hematopoietic, lymphoid
systems, gastrointestinal tract, and heart [8].
Discodermolidea I Mice Immunosuppresive [10].
Yondelis II/III
Mice, rats,
Reversible hepatobiliary toxicity in monkeys [11].
monkeys Hematotoxic at MTD 600µg/m2 in mice [12].
Hepatotoxic in rats [13].
Squalamine II Monkeys
Systemic squalamine injection inhibited the
development of iris neovascularization and caused partial
regression of new vessels in a primate model [14]
Kahalalide F I Rats
MTD is 1800µg/m2; no-adverse-eﬀect dose
is 480µg/m2/day; nephrotoxic and neurotoxic [15].
Aplidin II Mice More toxic eﬀects with prolonged exposure [8].
KRN7000b IN / AN / A [ 4, 8]
Cryptophycin-52 II N/A N/A [8]
Epothilone B II N/A N/A [16]
LAF389c IN / AN / A [ 4, 16]
ILX651a IN / AN / A [ 4]
HTI286 I N/A N/A [4, 17]
N/A = not available.
a Dolastatin-15 analogue.
b Agelasphin analouge (alpha-galactosylceramide).
c Bengamide B analouge.
One of the most promising marine compounds made
to the human clinical trials was didemnin B, a cyclic pep-
tide isolated from the Caribbean tunicate Trididemnum
solidum with antiviral and immunosuppressive activity
[22]. It was one of the very ﬁrst marine compounds en-
tered into the human clinical trials conducted simulta-
neously by several groups for treatment of various can-
cers [6, 23]. It has shown ineﬀectiveness to moderate an-
ticancer response in diﬀerent target sites and always in-
variably accompanied with high toxicity to the patients
[24, 25, 26, 27, 28, 29]. However, ultimately due to its ex-
treme toxicity, it was withdrawn from the phase II clini-
cal trials [1, 4, 6]. Recent literature search on the MED-
LINE for didemnin B resulted in 102 publications in
the peer-reviewed journals without ﬁnding a single study
on the preclinical anticancer evaluation of didemnin B
in pre-initiation animal carcinogenesis models. However,
the agent demonstrated antitumor activity against a va-
riety of tumor xenograft models [6, 8]. Animal toxic-
ities in CD2F1 mice, F344 rats, and beagle dogs were
also reported in lymphoid system, gastrointestinal tract,
liver, and kidney [8]. Further, dehydrodidemnin B or ap-
lidin, an oxidation analog of didemnin B, isolated from
Mediterranean tunicate Aplidium albicans with presum-
ably more potent anticancer potential is also being devel-
oped for its phase I clinical trials in Europe [3, 30]. How-
ever, without proper preclinical evaluation for this com-
pound, it may also meet the same fate as didemnin B.
Similarly, girolline and jaspamide, isolated from the
spongePseudoaxyssacantharella[31]andtheIndo-Paciﬁc
sponge Jaspis splendus [32], respectively, were also with-
drawn from the clinical trials due to their extremely toxic
side eﬀects. Girolline resulted in hypertension problems
in the patients while jaspamide was withdrawn gracefully
from the preclinical evaluation stage because it was too
toxic [5]. Literature search on both of these compounds
resulted in 115 published reports for jaspamide but none
were found for girolline. Out of 115 published articles for
jaspamide,noreportonitstoxicityoranticancerpotential
in the rodent models was found.
Yondelis, a promising anticancer compound, is cur-
rently in phase II and phase III clinical trials and has2004:2 (2004) Novel Marine Compounds 95
been approved as an Orphan Drug [4]. However, sub-
stantial hepato- and hemato-toxicities of Yondelis in rats,
mice, and monkeys could actually limit its potential use
in the human cancer treatment (Table 1)[ 11, 12, 13].
However, recent study showed that high dose of dexam-
ethasone oﬀered complete protection against the hepa-
totoxicity in rats by yondelis [13]. Another anticancer
compound, LU103793, a dolastatin 15 analogue, has
failed to show activity in patients with melanoma and
breast cancer in phase II trials, however, trials are ongo-
ing in ovarian, prostate, and colon cancer patients [33,
34]. Besides their therapeutic eﬃcacy studies in tumor
xenograft models, these compounds along with many
others have not been evaluated for their anticancer poten-
tials in the chemical/oncogene-induced animal carcino-
genesis models.
IMPORTANCE OF BIOMARKERS
Genotoxic and anticancer proﬁles for the majority
of the marine compounds currently in the clinical trials
are scarcely available. A few reports appeared regarding
the genotoxicity of marine compounds in vitro. Most of
them employed relatively nonspeciﬁc and superﬁcial as-
says (eg, Ames Salmonella, SOS induction, micronuclei,
sister chromatid exchange, and mutatox) for measuring
genotoxic potential [35, 36]. Further, the majority of the
articles published so far have considered the cytotoxicity,
apoptosis, and/or cell proliferation assays as benchmark
screening tools/markers for assessing the anticancer po-
tentialofacompound.However,themajorityofbiomark-
ers currently in use have not been rigorously validated
[37]. Thus far, there is no one universal biomarker for
malignant neoplastic diseases. It is therefore possible that
more than one biomarker, for example, DNA adducts,
gene expression, and DNA repair activity may need to be
considered for assuring the anticancer potential of a com-
pound.
Central dogma of carcinogenesis involves multiple
steps of initiation, promotion, and progression which si-
multaneously also provides numerous opportunities for
chemoprevention and/or therapeutic strategies. One of
the widely accepted notions is that the covalent DNA
adductformationrepresentsaprerequisitestepinthepro-
cess of cancer initiation. Further, DNA adducts represent
the net balance between the metabolism, detoxiﬁcation,
and to certain extent the DNA repair and therefore have
been considered as an excellent intermediary biological
marker to study the genotoxic and anticancer potentials
of compounds [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
49, 50, 51, 52, 53].
The applicability of DNA adducts as early biomark-
ers in carcinogenesis and cancer prevention studies is
supported by several facts: (i) carcinogen-DNA adduct
formation, their presence and levels in animals and hu-
mans correlate with carcinogen exposure (reviewed in
[39, 40]); (ii) the presence of DNA adducts in humans
has been associated with an increased risk for cancer de-
velopment [41]; (iii) the adduct forming capacity, muta-
genic and carcinogenic potentials correlate for many car-
cinogens [42, 43, 44]; (iv) the inhibition of carcinogen-
induced DNA adducts both in vitro and in vivo gener-
ally classiﬁes a compound to be a probable anticancer
[45, 46, 47, 48, 49, 50]; and (v) inhibition of DNA adducts
by chemopreventive agents has been correlated with de-
creased tumorigenesis in animals [51, 52, 53].
Despite the fact that several marine anticancer com-
pounds are considered to be DNA-interactive, causing
from reductive DNA cleavage [54]t oD N Aa d d u c tf o r m a -
tion [55], not much attention has been given to the DNA
adduct as early biomarker in the development of marine
anticancer drugs. In our continuous eﬀort to search for
new potential anticancer compounds, we have screened
few marine compounds for their genotoxic and chemo-
preventive potentials using benzo[a]pyrene (BP)-derived
DNA adducts as endpoint biomarker in MCF-7 cells as
described by Smith et al [47]. These new marine com-
pounds, for example, manzamine A, sarcophine, curcud-
iol, curcuphenol, aaptamine, and verongiaquinol were re-
ported in the literature with antimalarial, antiviral, and
antitumor activities [56, 57, 58, 59, 60, 61, 62, 63, 64].
Manzamine A and sarcophine were reported to have anti-
canceractivity[56,59,64].Sarcophine,afuranocembrane
diterpene, isolated from the Red Sea soft coral Sarcophy-
ton glaucum, was found to serve as an eﬀective inhibitor
of JB6 cell transformation [59]. A substantial increase (up
to 400%) was noticed in the BP diol epoxide-DNA adduct
formationintheMCF-7cellsbynearlyallthecompounds
(Arif, Kunhi, Siddiqui, El-Sayed, Orabi, Al-Hazzani, Al-
Ahdal,Al-Khodairy,manuscriptinpreparation).Interest-
ingly, sarcophine (100µM) and manzamine A (50µM),
the probable anticancer compounds, were of the signiﬁ-
cant inducers of BP-DNA adduct formation. These ma-
rine compounds themselves did not actually form any
lipophilic DNA adducts, however, they modulated the
DNA adduct formation by BP suggesting that they could
enhance the DNA adduction in the animal and/or hu-
man tissues which could be preexposed to diﬀerent car-
cinogens via diet and environment. Though the mecha-
nism(s) of increased BP-DNA adduct formation by these
compounds is not known, it could be due to modulation
in the metabolic activation (phase I enzymes), detoxiﬁca-
tion (phase II enzymes) and/or DNA repair. Based on the
preliminary data, sarcophine and manzamine A may be
considered as probable genotoxic rather than anticancer
compounds and they should be cross-examined using ad-
ditional biomarkers prior to be tested in the animal mod-
els and human clinical trials. This being the ﬁrst observa-
tion with the marine compounds using DNA adducts as
intermediary biomarker further stresses the importance
of DNA adducts in assuring the anticancer potential of
new compounds. Further studies on DNA repair and re-
latedgeneswithmarinecompoundsareinprogressinour
laboratory.96 Jamal M. Arif et al 2004:2 (2004)
CONCLUSIONS
In the past several decades, thousands of marine com-
pounds with tremendous pharmacological activities have
been isolated and more than a dozen of them are in diﬀer-
ent stages of human clinical trials against various diseases.
However, several of the known marine compounds were
alsowithdrawnprematurelyfromclinicaltrialsbecauseof
their extremely toxic side eﬀects. Most of these anticancer
marine compounds currently in clinical trials utilize their
therapeutic potentials were tested in short-term animal
studies using human tumor xenografts, however, only
two compounds (Cytarabine and KRN7000) were tested
in chemical- and/or oncogene-induced pre-initiation ani-
mal carcinogenesis models for their anticancer potentials.
In summary, it is the time to carefully and thoroughly
screen any marine compound for anticancer and geno-
toxic potentials using variety of biomarkers in animal car-
cinogenesis models prior to their entry into the clinical
trials, otherwise, there may be no surprise that they could
also meet similar fate as didemnin B and others with
substantial setback to the marine drug development pro-
grams.
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